{"id":815205,"date":"2026-05-25T19:10:01","date_gmt":"2026-05-25T19:10:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=815205"},"modified":"2026-05-25T19:10:01","modified_gmt":"2026-05-25T19:10:01","slug":"redefining-the-mrna-supply-chain-innovation-beyond-intellectual-property-barriers","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/redefining-the-mrna-supply-chain-innovation-beyond-intellectual-property-barriers_815205.html","title":{"rendered":"Redefining the mRNA Supply Chain: Innovation Beyond Intellectual property Barriers"},"content":{"rendered":"

From Lab Bench to Patent Throne: Vazyme’s Proprietary T7 Mutant C10 Patent Approved (CN202411429549.2) – Accelerating mRNA Therapeutics for Humanity!<\/p>\n

Vazyme’s Self-Developed T7 Mutant C10 Granted Patent Approval in China, Marking a Major Breakthrough in mRNA Raw Material Innovation.On May 20, 2025, Vazyme’s independently developed T7 RNA Polymerase Variant—C10—was officially granted patent approval by the China National Intellectual Property Administration (CNIPA). This milestone represents a significant advancement in the innovation of core raw materials for mRNA technology.<\/p>\n

The successful approval of T7 Mutant C10 (https:\/\/www.vazymeglobal.com\/product-center\/mrna-r-d-reagents\/t7-rna-polymerase-variants-toolbox<\/a>) provides an efficient and high-performing alternative for mRNA development and manufacturing. This achievement not only enhances cost-effectiveness but also paves the way for more scalable and accessible mRNA therapeutics. Vazyme remains committed to driving the high-quality development of the global mRNA industry chain through continuous innovation.<\/p>\n

\"Redefining<\/p>\n

T7 RNAP Variant-C10<\/strong><\/p>\n

Through rigorous validation, our T7 Variant C10 delivers game-changing cost efficiency for mRNA capping:<\/p>\n

\u2705 95% reduction in Cap analog usage (via enhanced KdCap\/KdNTP ratio)<\/p>\n

\u2705 Compatibility with wild-type T7 promoters (GG)<\/p>\n

\u2705 Comparable CQA to T7 WT<\/p>\n

\u2705 Tested and confirmed across various mRNA sequences<\/p>\n

\"Redefining<\/p>\n

This breakthrough slashes production costs while maintaining high-performance standards, making scalable mRNA therapies more accessible than ever.<\/p>\n

Beyond C10: A Robust Pipeline of Innovation<\/strong><\/p>\n

T7 Mutant C10 is just the beginning. Vazyme has built a strategic patent portfolio with 10+ additional T7 mutant patents currently under review – solidifying our leadership in mRNA enzyme engineering and ensuring long-term freedom-to-operate for partners worldwide.<\/p>\n

At Vazyme, our world-class team of biologists and innovators is relentlessly pushing boundaries. We’re committed to delivering cutting-edge tools and solutions that empower mRNA pioneers across the globe. Every patent, every discovery, brings us closer to a future where life-saving mRNA therapies reach patients faster, smarter, and at scale.<\/p>\n

Join us in redefining what’s possible. Let’s accelerate the mRNA revolution – together.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Vazyme<\/a>
Email:<\/strong> Send Email<\/a>
Country:<\/strong> China
Website:<\/strong> https:\/\/www.vazymebiotech.com\/<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

From Lab Bench to Patent Throne: Vazyme’s Proprietary T7 Mutant C10 Patent Approved (CN202411429549.2) – Accelerating mRNA Therapeutics for Humanity! Vazyme’s Self-Developed T7 Mutant C10 Granted Patent Approval in China, Marking a Major Breakthrough in mRNA Raw Material Innovation.On May … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,410,403,404,416],"tags":[],"class_list":["post-815205","post","type-post","status-publish","format-standard","hentry","category-Business","category-Manufacturing-Industry","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/815205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=815205"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/815205\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=815205"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=815205"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=815205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}